RIBAVIRIN DOES NOT IMPACT HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS ON OMBITASVIR/ PARITAPREVIR /RITONAVIR AND DASABUVIR AT THE END OF 12-WEEK TREATMENT IN TREATMENT-NAIVE ADULTS WITH GENOTYPE 1A (GT1A) CHRONIC HEPATITIS C

被引：0
|
作者：
Liu, Y. [1 ]
Bernstein, D. [2 ]
Larsen, L. [1 ]
Luo, Y. [1 ]
Xie, Y. [1 ]
Juday, T. [1 ]
机构：
[1] AbbVie Inc, N Chicago, IL USA
[2] N Shore Univ Hosp, Manhasset, IL USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI30
引用
收藏
页码：A227 / A227
页数：1
相关论文
共 50 条
  • [21] Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection
    Perello, C.
    Carrion, J. A.
    Ruiz-Antoran, B.
    Crespo, J.
    Turnes, J.
    Llaneras, J.
    Lens, S.
    Delgado, M.
    Garcia-Samaniego, J.
    Garcia-Paredes, F.
    Fernandez, I.
    Morillas, R. M.
    Rincon, D.
    Porres, J. C.
    Prieto, M.
    Lazaro Rios, M.
    Fernandez-Rodriguez, C.
    Hermo, J. A.
    Rodriguez, M.
    Herrero, J. I.
    Ruiz, P.
    Fernandez, J. R.
    Macias, M.
    Pascasio, J. M.
    Moreno, J. M.
    Serra, M. A.
    Arenas, J.
    Real, Y.
    Jorquera, F.
    Calleja, J. L.
    JOURNAL OF VIRAL HEPATITIS, 2017, 24 (03) : 226 - 237
  • [22] Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis
    Hsieh, Yi-Chung
    Jeng, Wen-Juei
    Huang, Chien-Hao
    Teng, Wei
    Chen, Wei-Ting
    Chen, Yi-Cheng
    Lin, Shi-Ming
    Tai, Dar-In
    Lin, Chun-Yen
    Sheen, I-Shyan
    PLOS ONE, 2018, 13 (08):
  • [23] An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naive Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)
    Asselah, Tarik
    Moreno, Christophe
    Sarrazin, Christoph
    Gschwantler, Michael
    Foster, Graham R.
    Craxi, Antonio
    Buggisch, Peter
    Ryan, Robert
    Lenz, Oliver
    Scott, Jane
    Van Dooren, Gino
    Lonjon-Domanec, Isabelle
    Schlag, Michael
    Buti, Maria
    PLOS ONE, 2016, 11 (07):
  • [24] Efficacy and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir with ribavirin in adults with genotype 1 or genotype 4 chronic hepatitis C virus infection and child-pugh B decompensated cirrhosis
    Mantry, P.
    Reddy, R.
    Cohen, E.
    Everson, G.
    Ramji, A.
    Zeuzem, S.
    Gordon, S.
    Yoshida, E.
    Sherman, M.
    Balart, L.
    Baumgarten, A.
    Lee, S.
    Fredrick, L. M.
    Abunimeh, M.
    Cohen, D. E.
    Shulman, N. S.
    Wilson, J.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S728 - S729
  • [25] Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir and dasabuvir combination with or without ribavirin in difficult-to-treat genotype 1 chronic hepatitis C patients in Hong Kong
    Chan, Henry L. Y.
    Tsang, Owen T. Y.
    Hui, Yee Tak
    Fung, James Y. Y.
    Lui, Grace C. Y.
    Lai, Ching Lung
    Lo, Angeline O. S.
    Chan, Kam Hon
    But, David Y. K.
    Lao, Wai Cheung
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 378 - 378
  • [26] PREDICTORS OF HEPATIC DECOMPENSATION DURING OMBITASVIR/PARITAPREVIR/RITONAVIR ± DASABUVIR ± RIBAVIRIN TREATMENT OF GENOTYPE 1 AND 4 HCV INFECTED PATIENTS (REAL LIFE AMBER STUDY)
    Flisiak, R.
    Jaroszewicz, J.
    Janczewska, E.
    Wawrzynowicz-Syczewska, M.
    Grabinska, A.
    Bolewska, B.
    Pisula, A.
    Karpinska, E.
    Mozer-Lisewska, I.
    Madej, G.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S815 - S815
  • [27] Direct-Acting Antivirals Ombitasvir / Paritaprevir / Ritonavir plus Dasabuvir with or Without Ribavirin in Hepatitis C Virus (HCV) Genotype 1-Infected Treatment-Naive or Treatment-Experienced Patients with or Without Cirrhosis: Real-Life Experience in Lithuania and Latvia
    Jancoriene, Ligita
    Polubenko, Katazyna
    Kazenaite, Edita
    Buivydiene, Arida
    Jakutiene, Jolita
    Tolmane, Ieva
    Jeruma, Agita
    Radzisauskiene, Daiva
    Mockiene, Evelina
    Ambrozaitis, Arvydas
    HEPATITIS MONTHLY, 2018, 18 (01)
  • [28] GEODE-II: Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Low-Dose Ribavirin QD in Patients with Genotype 1a Chronic Hepatitis C Virus Infection without Cirrhosis
    Poordad, Fred
    Sedghi, Shahriar
    Pockros, Paul J.
    Ravendhran, Natarajan
    Reindollar, Robert
    Lucey, Michael R.
    Epstein, Michael S.
    Bank, Leslie
    Bernstein, David E.
    Trinh, Roger
    Krishnan, Preethi
    Pilot-Matias, Tami
    Polepally, Akshanth R.
    Pothacamury, Rajvineeth K.
    Unnebrink, Kristina
    Martinez, Marisol
    Nelson, David R.
    HEPATOLOGY, 2016, 64 : 431A - 432A
  • [29] Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort
    Sperl, Jan
    Kreidlova, Miluse
    Merta, Dusan
    Chmelova, Klara
    Senkerikova, Renata
    Frankova, Sona
    KIDNEY & BLOOD PRESSURE RESEARCH, 2018, 43 (02): : 594 - 605
  • [30] Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection
    Bernstein, David
    Tripathi, Rakesh
    Cohen, Daniel E.
    HEPATIC MEDICINE-EVIDENCE AND RESEARCH, 2019, 11 : 35 - 40
12345